Acorah Software Products - Accounts Production 19.3.550 false true 31 October 2024 1 November 2023 false 1 November 2024 31 October 2025 31 October 2025 09836447 Dr S Beheshti Mr J Smith iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 09836447 2024-10-31 09836447 2025-10-31 09836447 2024-11-01 2025-10-31 09836447 frs-core:CurrentFinancialInstruments 2025-10-31 09836447 frs-core:Non-currentFinancialInstruments 2025-10-31 09836447 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-11-01 2025-10-31 09836447 frs-core:OtherResidualIntangibleAssets 2025-10-31 09836447 frs-core:OtherResidualIntangibleAssets 2024-11-01 2025-10-31 09836447 frs-core:OtherResidualIntangibleAssets 2024-10-31 09836447 frs-core:ShareCapital 2025-10-31 09836447 frs-core:RetainedEarningsAccumulatedLosses 2025-10-31 09836447 frs-bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 09836447 frs-bus:FilletedAccounts 2024-11-01 2025-10-31 09836447 frs-bus:SmallEntities 2024-11-01 2025-10-31 09836447 frs-bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 09836447 frs-bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 09836447 frs-bus:Director1 2024-11-01 2025-10-31 09836447 frs-bus:Director2 2024-11-01 2025-10-31 09836447 frs-countries:EnglandWales 2024-11-01 2025-10-31 09836447 2023-10-31 09836447 2024-10-31 09836447 2023-11-01 2024-10-31 09836447 frs-core:CurrentFinancialInstruments 2024-10-31 09836447 frs-core:Non-currentFinancialInstruments 2024-10-31 09836447 frs-core:ShareCapital 2024-10-31 09836447 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31
Registered number: 09836447
VITA PHARMED LIMITED
Financial Statements
For The Year Ended 31 October 2025
VITA PHARMED LIMITED
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
VITA PHARMED LIMITED
Balance Sheet
As At 31 October 2025
Balance Sheet
Registered number: 09836447

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 1,610 |  | 90
|  |  | 1,610 |  | 90
CURRENT ASSETS
Debtors | 5 | 8,526 |  | 33,832 |
Cash at bank and in hand |  | 6,707 |  | 12,685 |
|  | 15,233 |  | 46,517 |
Creditors: Amounts Falling Due Within One Year | 6 | (11,996 ) |  | (46,582 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 3,237 |  | (65 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 4,847 |  | 25
Creditors: Amounts Falling Due After More Than One Year | 7 |  | (297,088 ) |  | (269,705 )
NET LIABILITIES |  |  | (292,241 ) |  | (269,680 )
CAPITAL AND RESERVES
Called up share capital | 8 |  | 100 |  | 100
Profit and Loss Account |  |  | (292,341 ) |  | (269,780 )
SHAREHOLDERS' FUNDS |  |  | (292,241) |  | (269,680)

Page 1
Page 2
VITA PHARMED LIMITED
Balance Sheet (continued)
As At 31 October 2025
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Dr S Beheshti Director
14 July 2026

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
VITA PHARMED LIMITED
Notes to the Financial Statements
For The Year Ended 31 October 2025
Notes to the Financial Statements
1. General Information
VITA PHARMED LIMITED is a private company, limited by shares, incorporated in England & Wales, registered number 09836447 . The registered office is 3 Wellesley House, Horton Crescent, Epsom, KT19 8BQ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets are intellectual property. It is amortised to profit and loss account over its estimated economic life of 10 years.
2.4. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2024: 1)
1 1
Page 3
Page 4
VITA PHARMED LIMITED
Notes to the Financial Statements (continued)
For The Year Ended 31 October 2025
4. Intangible Assets

| Other
--- | ---
| £
Cost
As at 1 November 2024 | 100
Additions | 1,700
As at 31 October 2025 | 1,800
Amortisation
As at 1 November 2024 | 10
Provided during the period | 180
As at 31 October 2025 | 190
Net Book Value
As at 31 October 2025 | 1,610
As at 1 November 2024 | 90

5. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 7,056 |  | 30,915
Other debtors | 1,470 |  | 2,917
| 8,526 |  | 33,832

6. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 9,716 |  | 42,428
Other creditors | 2,280 |  | 3,934
Taxation and social security | - |  | 220
| 11,996 |  | 46,582

7. Creditors: Amounts Falling Due After More Than One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Other creditors | 297,088 |  | 269,705

Page 4
Page 5
VITA PHARMED LIMITED
Notes to the Financial Statements (continued)
For The Year Ended 31 October 2025
8. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 100 |  | 100

9. Related Party Transactions
Included in other creditors due more than one year was £297,088 (2024: £269,705) due to Dr S H R Beheshti, the director of the company.
10. Going concern
The company continues to meet its obligations through trading activities and with the support of the director, who has confirmed that he will not draw down on his loan in advance of creditors being paid.
Page 5